AIFM2 and metastatic melanoma: In two recent studies published in Nature, Wu et al. and Palma et al. elegantly demonstrated that the endogenous ferroptosis suppressor AIF family member 2 (AIFM2, best known as FSP1) is a pharmacologically actionable vulnerability in lung carcinoma and metastatic melanoma.1,2 These findings formally validate the notion that activating ferroptosis might constitute a viable strategy to control developing tumors (which often exhibit defects in apoptotic signaling),3 potentially paving the way to the development of clinically viable ferroptosis inducers for cancer therapy.